Searched for
CHRISTIANE HAMACHER
Biocon Biologics to expand to Latin America, Africa and Asia“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...09 Nov, 2020, 09.04 PM IST- Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures“The Board of its (Biocon’s) subsidiary Biocon Biologics has approved a Rs 1,125 Crore ($150 million) capital injection from Goldman Sachs....07 Nov, 2020, 04.28 PM IST
- Tata Capital picks up 0.85% stake in Biocon Biologics for $30 millionPost the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.31 Jul, 2020, 09.35 AM IST
- Biosimilar drugs can help us reach $1 billion target soon: Christiane Hamacher, CEO, Biocon BiologicsIt is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.16 Jun, 2020, 11.03 AM IST
- Biocon says use of Itolizumab in COVID-19 treatment encouragingBiocon has witnessed encouraging results in the use of its novel biologic Itolizumab for treating some Covid-19 related conditions, the pha...16 May, 2020, 09.11 AM IST
- Biocon jumps 4% on launch of drug Fulphila in CanadaBiocon has shared or co-exclusive commercialisation rights with Mylan for the product in the rest of the world.29 Apr, 2020, 03.43 PM IST
- Biocon, Mylan launch cancer drug in CanadaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...28 Apr, 2020, 09.42 PM IST
- Biocon, Mylan launch cancer drug in AustraliaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...14 Apr, 2020, 10.30 AM IST
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...09 Mar, 2020, 10.13 AM IST
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...06 Jan, 2020, 07.56 PM IST
- Biocon sees a sweet spot with its affordable insulin in USThe biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...05 Dec, 2019, 08.22 AM IST
- Biocon rises 5% after launch of Ogivri in US marketBiotechnology major Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast...03 Dec, 2019, 03.44 PM IST
- Biocon, Mylan launch cancer drug in US marketOgivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and met...02 Dec, 2019, 06.45 PM IST
- Volume with low cost is Biocon Biologics’ big planThe Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosyst...02 Dec, 2019, 09.53 AM IST
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...27 Nov, 2019, 05.22 PM IST
- Biocon Biologics debuts in Asia IP Elite listBiocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELI...12 Nov, 2019, 07.34 PM IST
- Lara Bezerra to take over as Roche Products India MDLara has over 24 years of experience in the pharmaceutical industry and was earlier the general manager of Roche Venezuela.14 Nov, 2017, 12.42 PM IST
Load More
